Last reviewed · How we verify

High-dose dexmedetomidine — Competitive Intelligence Brief

High-dose dexmedetomidine (High-dose dexmedetomidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Critical Care / Anesthesia.

marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Critical Care / Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

High-dose dexmedetomidine (High-dose dexmedetomidine) — Tang-Du Hospital. High-dose dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
High-dose dexmedetomidine TARGET High-dose dexmedetomidine Tang-Du Hospital marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor
oxymetazoline-fluticasone propionate oxymetazoline-fluticasone propionate Brian J Lipworth marketed Nasal decongestant/corticosteroid combination Alpha-2 adrenergic receptor; glucocorticoid receptor
Brimonidine/Timolol mixed combination Brimonidine/Timolol mixed combination Seoul National University Hospital marketed Alpha-2 adrenergic agonist / Beta-blocker combination Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors
Clonidine Oral Liquid Product Clonidine Oral Liquid Product Region Örebro County marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor
Catapresan TTS 2 Catapresan TTS 2 Heart Care Foundation marketed Central alpha-2 adrenergic agonist Alpha-2 adrenergic receptor
Combigan Ophthalmic Solutiom Combigan Ophthalmic Solutiom Genovate Biotechnology Co., Ltd., marketed Fixed-dose combination of alpha-2 adrenergic agonist and beta-adrenergic antagonist Alpha-2 adrenergic receptors and beta-adrenergic receptors
Clonidine Pill Clonidine Pill Weill Medical College of Cornell University marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

  1. Allergan · 3 drugs in this class
  2. Eye & ENT Hospital of Fudan University · 2 drugs in this class
  3. National Cancer Institute, Egypt · 2 drugs in this class
  4. The University of Hong Kong · 2 drugs in this class
  5. Sindh Institute of Urology and Transplantation · 2 drugs in this class
  6. Fayoum University Hospital · 1 drug in this class
  7. First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
  8. Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
  9. Icahn School of Medicine at Mount Sinai · 1 drug in this class
  10. KAT General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). High-dose dexmedetomidine — Competitive Intelligence Brief. https://druglandscape.com/ci/high-dose-dexmedetomidine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: